Table 3 Univariate analysis of prognostic factors in patients treated with RFA after first-line treatment with TACE
Variable | No. of patients (%) | OS (months) | P value |
|---|---|---|---|
Age (years) | Â | Â | Â |
 ≥60 | 18 (40) | 34 | 0.708 |
 <60 | 27 (60) | 27 |  |
Gender | Â | Â | Â |
 Male | 39 (86.7) | 34 | 0.388 |
 Female | 6 (13.3) | 20 |  |
AFP | Â | Â | Â |
 ≥400 ng/ml | 20 (44.4) | 20 | 0.015 |
 <400 ng/ml | 25 (55.6) | 43 |  |
Lesion size | Â | Â | Â |
 ≥50 mm | 41 (91.1) | 41 | 0.028 |
 <50 mm | 4 (8.9) | 22 |  |
Lesion number | Â | Â | Â |
 Single | 10 (22.2) | 29 | 0.888 |
 Multiple | 35 (77.8) | 28 |  |
ALT | Â | Â | Â |
 ≥75 U/L | 9 (20.0) | 38 | 0.828 |
 <75 U/L | 36 (80.0) | 42 |  |
GGT | Â | Â | Â |
 ≥100 U/L | 21 (46.7) | 34 | 0.869 |
 <100 U/L | 24 (53.3) | 27 |  |
ALB | Â | Â | Â |
 ≥35 g/L | 38 (84.4) | 34 | 0.078 |
 <35 g/L | 7 (15.6) | 20 |  |
PT | Â | Â | Â |
 ≥13 s | 7 (15.6) | 20 | 0.059 |
 <13 s | 38 (84.4) | 34 |  |